253 related articles for article (PubMed ID: 12629207)
1. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
2. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.
Mao Y; Desai SD; Ting CY; Hwang J; Liu LF
J Biol Chem; 2001 Nov; 276(44):40652-8. PubMed ID: 11546768
[TBL] [Abstract][Full Text] [Related]
3. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
5. The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1).
Isik S; Sano K; Tsutsui K; Seki M; Enomoto T; Saitoh H; Tsutsui K
FEBS Lett; 2003 Jul; 546(2-3):374-8. PubMed ID: 12832072
[TBL] [Abstract][Full Text] [Related]
6. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
[TBL] [Abstract][Full Text] [Related]
7. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
[TBL] [Abstract][Full Text] [Related]
8. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
Desai SD; Zhang H; Rodriguez-Bauman A; Yang JM; Wu X; Gounder MK; Rubin EH; Liu LF
Mol Cell Biol; 2003 Apr; 23(7):2341-50. PubMed ID: 12640119
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.
Lin RK; Ho CW; Liu LF; Lyu YL
J Biol Chem; 2013 Mar; 288(10):7182-92. PubMed ID: 23344961
[TBL] [Abstract][Full Text] [Related]
10. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
Elife; 2020 Feb; 9():. PubMed ID: 32057297
[TBL] [Abstract][Full Text] [Related]
11. SCF
Shu J; Cui D; Ma Y; Xiong X; Sun Y; Zhao Y
Oncogenesis; 2020 Feb; 9(2):8. PubMed ID: 32015321
[TBL] [Abstract][Full Text] [Related]
12. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
13. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
[TBL] [Abstract][Full Text] [Related]
14. Activation of a novel ubiquitin-independent proteasome pathway when RNA polymerase II encounters a protein roadblock.
Ban Y; Ho CW; Lin RK; Lyu YL; Liu LF
Mol Cell Biol; 2013 Oct; 33(20):4008-16. PubMed ID: 23938298
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
16. Acidic pH induces topoisomerase II-mediated DNA damage.
Xiao H; Li TK; Yang JM; Liu LF
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5205-10. PubMed ID: 12692309
[TBL] [Abstract][Full Text] [Related]
17. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
[TBL] [Abstract][Full Text] [Related]
19. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; So S; Koyama H
Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]